PEPG - Pepgen Inc

NYSE * Health Care * Biotechnology

$1.70

+$0.03 (+1.80%)

About Pepgen Inc

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

PEPG Key Statistics

Market Cap

$117.50M

0

P/B Ratio

0.79

EPS

$-2.12

Employees

56

How PEPG Compares to Peers

PEPG is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

#6

of 6

CompanyP/EGrowthCompare
PEPGN/A0%-
AMGN24.60%vs AMGN
GILD20.30%vs GILD
VRTX28.80%vs VRTX
REGN18.10%vs REGN
BIIB20.0-0%vs BIIB

Pepgen Inc Company Information

Headquarters
Massachusetts; U.S.A
Website
www.pepgen.com
Sector
Health Care
Industry
Biotechnology
Data Updated:
Ready to invest in PEPG?

Commission-free trading available. Affiliate links.

PEPG Lician Score

5% confidence
4.0/10
Neutral

PEPG has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates PEPGacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

PEPG Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

35810Value5.0Growth2.0Quality5.0Momentum5.0Safety5.04.4/10
5.0

Value

2.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for PEPG